List To Watch: LifeLock, Inc., Hingham Institution for Savings (NASDAQ:HIFS), Cytokinetics, Incorporated (NASDAQ:CYTK), Sorrento Therapeutics (NASDAQ:SRNE)

ADTRAN Inc. (NASDAQ:ADTN) shares advanced 0.07% in last trading session and ended the day at $14.72. ADTN Gross Margin is 46.00% and its has a return on assets of 3.60%. ADTRAN Inc. (NASDAQ:ADTN) quarterly performance is -9.46%.

ADTRAN, Inc. is a global provider of networking and communications equipment. The Company’s solutions enable voice, data, video and Internet communications across a variety of network infrastructures. The Company operates through two segments: the Carrier Networks Division and the Enterprise Networks Division. The Carrier Networks Division offers broadband and optical infrastructure products and services used by service providers to aggregate, transport, and deliver voice, data, and video services to their customers’ premises and mobile network cell sites.

LifeLock, Inc. (NYSE:LOCK) ended the last trading day at $8.63. Company weekly volatility is calculated as 4.18% and price to cash ratio as 2.52. LifeLock, Inc. (NYSE:LOCK) showed a weekly performance of -6.09%.

LifeLock, Inc. is a provider of proactive identity theft protection services for consumers and identity risk assessment and fraud protection services for enterprises. It operates in two segments: consumer segment, which offers offer identity theft protection services to consumers on a monthly or annual subscription basis, and an enterprise segment, which offers consumer risk management services to enterprise customers who pay it based on the monthly volume of transactions with the Company. As of December 31, 2014, the Company served approximately 3.6 million paying members. As of December 31, 2014, the Company served over 300 enterprise customers.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 21, 2015 deadline in the securities class action lawsuit filed on behalf of investors of LifeLock, Inc. (NYSE:LOCK) who purchased LifeLock securities between July 30, 2014 and July 20, 2015, inclusive (the “Class Period”). Investors who suffered losses in excess of $100,000 on their investment in LifeLock are encouraged to contact GPM to discuss their legal rights.

On 25 September, Hingham Institution for Savings (NASDAQ:HIFS) shares advanced 0.68% and was closed at $117.00. HIFS EPS growth in last 5 year was 22.50%. Hingham Institution for Savings (NASDAQ:HIFS) year to date (YTD) performance is 37.24%.

Hingham Institution for Savings is a Massachusetts-chartered savings bank located in Hingham, Massachusetts. Incorporated in 1834, it is the oldest financial institution headquartered in Hingham and one of the oldest continuously operating banks in the United States. The Bank’s main offices are located on Main Street in Hingham, MA.

HINGHAM INSTITUTION FOR SAVINGS (NASDAQ:HIFS), Hingham, Massachusetts announced that its Board of Directors declared a regular quarterly cash dividend of $0.30 per share. The dividend will be paid on October 20, 2015 to stockholders of record as of October 9, 2015.

Cytokinetics, Incorporated (NASDAQ:CYTK) shares decreased -9.63% in last trading session and ended the day at $6.76. CYTK has a return on assets of -15.00%. Cytokinetics, Incorporated (NASDAQ:CYTK) quarterly performance is 2.42%.

Cytokinetics, Incorporated is a clinical stage biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company’s drug candidates that are in clinical development are its skeletal muscle activators tirasemtiv and CK-2127107 and its cardiac muscle activator omecamtiv mecarbil. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility.

On September 4, 2015, Cytokinetics, Incorporated (NASDAQ:CYTK) entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time through Cantor Fitzgerald, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $40.0 million (the “Shares”). Under the Sales Agreement, Cantor Fitzgerald may sell Shares by any method permitted by law and deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the Common Stock or to or through a market maker.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) caters to the Healthcare space. Its weekly performance is -28.59%. On the last day of trading company shares ended up at $9.29. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) distance from 50-day simple moving average (SMA50) is -42.81%.

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics for addressing unmet medical needs in the United States, Europe, as well as international markets. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but it is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX), a non-opiate, ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor.

Sorrento Therapeutics (NASDAQ:SRNE)‘s stock had its “buy” rating reissued by equities research analysts at Brean Capital in a report issued on Monday, Marketbeat.com reports. They currently have a $26.00 price objective on the biopharmaceutical company’s stock. Brean Capital’s price objective would suggest a potential upside of 49.68% from the stock’s previous close.